II

ImageneBio Inc

IMA·NASDAQ

$5.63

+1.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$63.50M
EPS-10.7600
P/E Ratio-0.52
Earnings Date07/23/2026

ima

Operating Expenses

Last Annual Value

48.22M

3-Year CAGR

30%

5-Year CAGR

40%

10-Year CAGR

2%

II

ImageneBio Inc Competitors Analysis of Operating Expenses

IMA · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
48.22M
-16.7%21.8%N/A 
57.28M
18.3%-8.7%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
115.73M
-8.7%10.2%220.9%
25.74M
-11.5%10.4%31.5%
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
103.23M
1.3%2.4%9.6%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
7.39M
8.8%10.8%47.5%
28.95M
10.5%26.4%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
219.18M
36.5%54.5%19.7%
200.11M
-5.4%5.8%13.1%
49.39M
-6.1%-10.1%8.2%
46.14M
50.8%-22.8%N/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.63, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.63